MD Anderson researchers showed investigational NTX-301 stayed active in resistant AML by reactivating the Hippo pathway.
July 27, 2026
FDA Approvals
Reconsidering Venetoclax Dosing With Azole Antifungals
Grant Drew, PharmD; Kiwon Park, PharmD, et al.
April 16, 2026
Clinical Trials
North American Enrollment in Clinical Trials
Ming-Hei Tai, PharmD, BCOP
April 15, 2026
Clinical Trials
Patient Navigators as Catalysts in Cancer Clinical Trials
Mandi L. Pratt-Chapman, PhD, MA, HON-OPN-CG
April 9, 2026
Recent Updates
The latest breakthroughs, research highlights, and industry developments in oncology.
View More
FDA Approvals
Updates on recent FDA approvals, label expansions, and regulatory decisions that may affect everyday oncology practice.
View More
FDA Approvals
Reconsidering Venetoclax Dosing With Azole Antifungals
Grant Drew, PharmD; Kiwon Park, PharmD, et al.
April 16, 2026